Expert Financial Analysis and Reporting

Investment Conclusion Today’s announcement that Cadence (CADX) has entered into a settlement with Perrigo (PRGO) on patent litigation regarding Ofirmev is a positive. Uncertainty over the patent situation of Ofirmev has been a dark cloud over Cadence’s stock. This settlement is encouraging, but Cadence still has another generic challenger to deal with in Exela Pharma […]

Introduction I have just written a new report on NovaBay (NBY) called NovaBay’s Robust Clinical Pipeline Approaches Critical Clinical Trial Results in 2013. This blog is a summary of that more in-depth report. For readers who want to understand the reasoning behind the conclusions I present here, I would suggest that you refer to that […]

Investment Summary Northwest Biotherapeutics’ (NWBOD) stock price increased 94% on Friday, September 28 to $10.95 per share and investors are asking what happened. There was certainly a short squeeze on Friday, but I don’t think that was the sole reason. Northwest has traded under $1.00 for a very long time and this has prevented many […]

Northwest Biotherapeutics (NWBO.OB) announced a 1 for 16 reverse stock split. This is a first step in a planned public offering of up to $25 million and listing of the common stock on the NASDAQ Capital Market. The reverse stock split will increase the price of the stock from the pre-split price of $0.30 per […]

My Recent History on Discovery Laboratories On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at a price of $2.82; the report was called Surfaxin Should Be Approved on its March 6th PDUFA Date. I urged investors to buy the stock before the PDUFA date. When I issued the report, […]

ImmunoCellular (IMUC.OB) has issued a press release stating that Manish Singh has resigned as CEO. He will be succeeded in the interim by Dr. John Yu, a founder of the company. The reasons for the resignation were not explained, but there may be some relationship to recent activity on the part of bloggers questioning the […]

  I have just written a report on JNJ in which I reiterated my Buy recommendation. I don’t see a vibrant world economy in the next few years that will reduce pressure on healthcare spending and I think that JNJ will probably show growth in operational sales and earnings for in-line businesses in the 3% […]

I reiterate my Buy recommendation on Cadence. The Ofirmev launch has now gained traction as just reported 2Q, 2012 revenues of $11.1 million exceeded guidance of $10.0 to $10.4 million. Management guidance for 3Q, 2012 of $13.7 to $14.2 million is better than the existing Street consensus of $13.6 million. The metrics for gauging the […]

In my recent article Spectrum Pharmaceuticals: The Bull and the Bear Case, I wrote about the tug of war between bears and bulls on Spectrum Pharmaceuticals. There are several elements to the bear case that has resulted in a short position that amounts to 52% of the float. The centerpiece of the bear argument has […]

  I am starting my coverage of Northwest Biotherapeutics (NWBO.OB) with a Buy. I became interested in this small bulletin board company based on research that I did on Dendreon (DNDN) whose prostate cancer vaccine Provenge is the first approved cancer therapeutic that uses living dendritic cells. I came to believe that this technology had […]